IRadimed Q2 FY26 GAAP diluted EPS drops 9% to $0.41; revenue rises 0.5% to $20.5 million

• IRadimed posted Q2 GAAP diluted EPS of $0.41, down 9% year over year, as revenue edged up 0.5% to $20.5 million.
• Net income fell 10% to $5.2 million; gross margin narrowed 4 percentage points to 74%.
• Non-GAAP diluted EPS was $0.46, down 7%; cash flow from operations dropped 23% to $5.9 million.
• Launched the new 3870 MR IV pump, with initial shipments meeting plan; said domestic monitor unit bookings set a record.
• Forecast Q3 revenue of $23 million-$24.5 million; reaffirmed full-year revenue guidance of $91 million-$96 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IRadimed Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607310815PRIMZONEFULLFEED9801357) on July 31, 2026, and is solely responsible for the information contained therein.